Strikingly, KRAS mutation status showed no significant correlation with age, sex, tumor size, histology, metastatic pattern, or TNM stage suggesting its role as an independent molecular driver rather than a surrogate for conventional prognostic markers.<h4>Conclusion</h4>These findings underscore the high prevalence of KRAS mutations in Algerian CRC patients and highlight their potential utility in refining therapeutic strategies, particularly for anti-EGFR eligibility. The gene discussed is KRAS; the disease is neoplasm.